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Penicillin-binding protein 2 (PBP2) from N. gonorrhoeae is
themajormolecular target for-lactam antibiotics used to treat
gonococcal infections. PBP2 from penicillin-resistant strains of
N. gonorrhoeaeharbors an aspartate insertion after position 345
(Asp-345a) and 4–8 additional mutations, but how these alter
the architecture of the protein is unknown.Wehave determined
the crystal structure ofPBP2derived fromthepenicillin-suscep-
tible strain FA19, which shows that the likely effect of Asp-345a
is to alter a hydrogen-bonding network involving Asp-346 and
the SXN triad at the active site. We have also solved the crystal
structure of PBP2 derived from the penicillin-resistant strain
FA6140 that contains fourmutations near the C terminus of the
protein. Although these mutations lower the second order rate
of acylation for penicillin by 5-fold relative towild type, compar-
ison of the two structures shows only minor structural differ-
ences, with the positions of the conserved residues in the active
site essentially the same in both. Kinetic analyses indicate that
twomutations, P551S and F504L, aremainly responsible for the
decrease in acylation rate. Melting curves show that the four
mutations lower the thermal stability of the enzyme. Overall,
these data suggest that the molecular mechanism underlying
antibiotic resistance contributed by the fourmutations is subtle
and involves a small but measurable disordering of residues in
the active site region that either restricts the binding of antibi-
otic or impedes conformational changes that are required for
acylation by -lactam antibiotics.
Neisseria gonorrhoeae, the causative agent of the sexually
transmitted infection, gonorrhea, is an obligate human patho-
gen that primarily colonizes the urogenital tract. For nearly 40
yearsN. gonorrhoeaewas treatedwith a single dose of penicillin,
but in 1987 the prevalence of penicillin-resistant strains neces-
sitated the use of alternative antibiotics (1), primarily fluoro-
quinolones and third-generation cephalosporins. The rapid
emergence and dissemination of fluoroquinolone-resistant
N. gonorrhoeae, however, leaves only third-generation cepha-
losporins (e.g. cefixime and ceftriaxone) as recommended
agents (1). Even though these cephalosporins are still effective
anti-gonococcal antibiotics, the increasing prevalence of
strains with intermediate resistance to these agents suggests
that full resistance is not far behind (2–5). These trends signal
an urgent need to understand the molecular mechanisms of
antibiotic resistance and to devise new treatment options for
gonococcal infections.
Themolecular targets of-lactam antibiotics are the penicil-
lin-binding proteins (PBPs),3 a group of enzymes involved in
the final stages of peptidoglycan synthesis in bacteria (6–8).
PBPs are grouped into three main classes, A, B, and C. Class A
and B PBPs are transpeptidases (TPases) that catalyze the for-
mation of peptide cross-links between adjacent glycan strands
of peptidoglycan, but are distinguished in that class A PBPs also
contain an N-terminal transglycosylase domain that polymer-
izes glycan strands, whereas class B PBPs possess only TPase
activity. Class C PBPs catalyze carboxypeptidase activity (and
sometimes endopeptidase activity) in vitro andmay function to
modulate the degree of cross-linking in peptidoglycan by
removing the terminal D-Ala of the peptide.
Four PBPs have been identified inN. gonorrhoeae (9, 10): two
high molecular mass transpeptidases, class A PBP1 and class B
PBP2, and two low molecular mass class C PBPs, PBPs 3 and 4.
Both PBP3 and PBP4, which catalyze carboxypeptidase and
endopeptidase activity in vitro (10, 11), can be deleted from
N. gonorrhoeaewith onlyminor effects on cell growth andmor-
phology (11), whereas PBPs 1 and 2 are essential for cell viability
and are the lethal targets of-lactamantibiotics (9, 12). Because
PBP2 is inhibited at 10-fold lower concentrations of penicillin
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than PBP1 in penicillin-susceptible strains, PBP2 is the primary
killing target of penicillin at its minimum inhibitory concentra-
tion (MIC) (9).
Chromosomally mediated penicillin-resistant strains of
N. gonorrhoeae arise through the stepwise acquisition of multi-
ple resistance determinants via DNA uptake and homologous
recombination (13, 14). These resistance determinants include
mutations of PBPs 1 and 2 that lower their susceptibility to
-lactam antibiotics (penA and ponA) (15, 16), mutations in
porin IB that reduce entry of antibiotics into the cell (penB) (17,
18), and increased expression of the MtrC-MtrD-MtrE efflux
pump that expels antibiotics from the periplasm (mtrR) (19,
20). Together, the mutations in high level penicillin-resistant
strains (e.g. FA6140) increase the MIC of penicillin 400–1000-
fold relative to a penicillin-susceptible strain (e.g. FA19).
The first step in the development of chromosomally medi-
ated penicillin resistance in N. gonorrhoeae is acquisition of
penA, which encodes altered forms of PBP2 (15, 21). Although
by itself the penA determinant accounts for a relatively small
contribution to penicillin resistance inN. gonorrhoeae, this first
step is requisite for the development of high level resistance.
Variants of PBP2 from penicillin-resistant strains very often
contain an aspartic acid insertion between amino acids 345 and
346 (termedAsp-345a orD-345a) alongwith 4–8 substitutions
near the C terminus of the protein (22, 23). Because PBP2 is an
essential enzyme, these mutations must remodel the active site
so as to lower the rate of acylation by penicillin without mark-
edly affecting its ability to function as a TPase. This is an
intriguing phenomenon because-lactam antibiotics are struc-
tural mimics of the peptide substrate (24) and react with the
same serine nucleophile at the active site of the enzyme (25).
How PBPs achieve this distinction at the molecular level
remains a subject of considerable interest (26–31).
Crystal structures of PBP2x and PBP1a from Streptococcus
pneumoniae (in both penicillin-sensitive and penicillin-resis-
tant forms) (27, 31–34) and of PBP2a frommethicillin-resistant
Staphylococcus aureus (28) have been used to propose mecha-
nisms of penicillin resistance in their respective organisms.
However, mechanistic interpretation has been hampered in
PBP2x and PBP1a by the large number of mutations between
the susceptible and resistant forms (e.g. PBP2x from strain
Sp328 contains 83mutations (27)) and in PBP2a by the lack of a
penicillin-susceptible counterpart. PBP2 from N. gonorrhoeae
is a more amenable system to understand the molecular basis
for penicillin resistance because only a small number of muta-
tions are responsible for conferring antibiotic resistance.
Here, we report the crystal structure of a soluble form of
PBP2 derived from a penicillin-susceptible strain (FA19) (35)
and of a construct derived from a penicillin-resistant strain
(FA6140) (14) of N. gonorrhoeae that contains four mutations
near the C terminus of the protein that are associated with
penicillin resistance. Even though the kinetic differences
between these proteins are significant, there is a surprising lack
of structural differences between the two proteins, suggesting a
very subtle molecular mechanism of antibiotic resistance.
Although a mutant protein containing Asp-345a could not be
crystallized, the crystal structure of the native protein suggests
that such an insertion will disrupt interactions involving the
SXNmotif of the enzyme.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—The sequence encod-
ing the periplasmic domain of PBP2 (residues 44–581) and a
four-amino acid spacer (Gly-Ser-Gly-Gly) was fused in-frame
to the C-terminal end of maltose-binding protein in the vector
pMAL-C2KV/H6 (11). pMAL-C2KV/H6 is similar to
pMAL-C2 (New England Biolabs, Beverly, MA) except that it
contains the kanamycin resistance gene in place of the -lacta-
mase gene, a tobacco etch virus protease cleavage site at the
junction of the two proteins, and six histidine residues between
the second and third amino acids of maltose-binding protein.
The maltose-binding protein-PBP2 fusion protein was puri-
fied from 2 liters of Escherichia coli GW6011 (MC4100
lon-146::Tn10) cells harboring the expression plasmid after
induction of the cells with 0.3 mM isopropyl--D-thiogalacto-
side for 2 h at 18 °C. Cells were harvested by centrifugation,
resuspended in 40 ml of buffer A (20 mM Tris, pH 8.0, 500 mM
NaCl, 10% glycerol) containing 2 mM EDTA and 1 mM phenyl-
methylsulfonyl fluoride, and lysed with an Emulsiflex-C5 dis-
rupter (Avestin, Ottawa, Canada). After centrifugation at
100,000  g to remove membranes and particulates, ammo-
nium sulfatewas added to 40% saturation, and precipitated pro-
teins were isolated by centrifugation at 15,000  g. The protein
pellet was resuspended in buffer A, filtered, and loaded onto a
Ni2-chelating affinity column (GE Healthcare). The column
was washed sequentially with 20 column volumes of buffer A
and 5 column volumes of buffer A with 15 mM imidazole, and
the fusion protein was eluted with a gradient of 15–300 mM
imidazole in buffer A. The purified fusion protein was dialyzed
at 4 °C for 3 h against buffer A to remove imidazole and simul-
taneously cleaved with His6-tagged tobacco etch virus protease
(50:1 weight ratio). PBP2 was isolated from the digest by a sec-
ond passage over Ni2-chelating affinity column. Minor con-
taminants eluted in the flow-through, whereas PBP2 (95%
purity) eluted in the 15 mM imidazole wash. The purified pro-
tein was concentrated to 5–7 mg/ml in buffer A (typical yields
were 30 mg protein/2 liters of culture).
Selenomethionine-substituted PBP2 was prepared by
expressing the protein in B834(DE3) methionine auxotroph
cells (Novagen, San Diego, CA) and growing in M9 minimal
media containing all amino acids except that selenomethionine
was used in place of methionine. This protein was purified in
the same way as for PBP2 except that 4 mM -mercaptoethanol
was added to all buffers.
PBP2 from FA6140 was amplified from genomic DNA with
the same gene-specific primers as for wild-type penA and
cloned into pMAL-C2KVH6. To create PBP2-6140CT and
PBP2-Asp-345a, a silent KpnI site was introduced at codons
366 and 367 in both wild type PBP2 and PBP2-6140 by the
QuikChange method (Stratagene, Carlsbad, CA), and the final
constructs were created by fragment exchange. All other
mutants were created in wild-type PBP2 by the QuikChange
method. Purification of these mutant PBP2 variants was
accomplished using the same protocol described above for
wild-type PBP2.
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Kinetic Analysis of PBP2 Variants—The kinetic scheme for
the interaction of a PBP with a -lactam antibiotic is,
E  S ¢O¡
KS






where ES is the non-covalent Michaelis complex, E-S is the
covalent acyl-enzyme complex, and P is the released product.
The constant k2/KS, in which KS  (k1  k2)/k1 describes the
initial rate of formation of covalent -lactam antibiotic-target
conjugates (E-S) at low (subsaturating) concentrations of-lac-
tam antibiotics (36). The deacylation rate of the penicilloyl-
PBP2 complex is very slow and can be ignored. The second
order k2/KS rate constants for acylation of PBP2 variants were
determined from time courses of formation of acyl-enzyme
complexes as described previously (11). In all cases, [14C]peni-
cillinGwas present in at least a 10-foldmolar excess over PBP2.
Crystallization—Crystals of PBP2 and PBP2-6140CT were
obtained by vapor diffusion over wells containing 2.0–2.4 M
ammonium sulfate buffered with 100 mM Tris, pH 8.0–8.5.
These rectangular-shaped prisms of approximate dimensions
0.5 0.1 0.3mmgrew after 2–3weeks of incubation at 21 °C.
A cryo-protecting solution was prepared by adding glycerol to
thewell solution in 2% increments up to a final concentration of
34%. Diffraction analysis revealed that the crystals belong to
space group P212121 with cell dimensions a  57.4, b  138.6,
and c  228.0 Å. There are two molecules in the asymmetric
unit, giving an estimated solvent content of 65% (37). Sel-
enomethionine-containing crystals were prepared in the same
manner.
Data Collection and Phasing—Data from selenomethionine-
containing crystals were collected at 100 K at beamline 9.2 of
the Stanford Synchrotron Radiation Laboratory (Stanford, CA)
on a Quantum 4 charge-coupled device detector using the
BLU-ICE environment (38). Data at three wavelengths were
collected, corresponding to the peak, inflection, and a high
energy remote, around the absorption edge of selenium using
inverse beam geometry in two 90° segments. These data were
processed at a resolution of 2.8 Å using DENZO and SCALE-
PACK (39) (supplemental Table 1). The structurewas solved by
SOLVE (40) and RESOLVE (41, 42) using only the first 90° of
the peak and remote data sets. Inclusion of the second wedge
of these data or of the inflection data set lowered the quality of
electron density maps, probably due to radiation damage. Sel-
enomethionine-substituted crystals of PBP2 diffracted slightly
better than native crystals, and therefore these crystals were
also used to collect a high resolution data set for refinement of
the structure. These data were processed using MOSFLM (43)
and SCALA (44) (Table 1). Data from crystals of PBP2-6140CT
were collected at the SER-CAT ID22 beamline of the Advanced
Photon Source on a Mar 300 charge-coupled device detector
and processed using HKL2000 (39) (Table 1).
Model Building and Refinement—Electron density maps
were displayed using O (45) and used to construct an initial
model. This was refined by iterative cycles of automated refine-
ment and manual revisions using O. Initial refinements used
XPLOR (46) but later rounds used REFMAC (47). Non-crystal-
lographic symmetry restraints were not used during the refine-
ment. 5%of reflectionswere set aside for the calculation of Rfree.
Solvent molecules were added using ARP/wARP (48). In later
roundsTLS parameterswere refined, where each domain of the
TABLE 1
X-ray diffraction data and refinement statistics
PBP 2 wild type PBP 2-6140CT
Data collection
Resolution range (Å) 87.0-2.30 (2.36-2.30) 50.0-2.4 (2.49-2.40)
Rmergea (%) 6.1 (34.9) 10.1 (52.0)
Redundancy 6.2 (3.7) 7.1 (4.3)
Completeness (%) 90.3 (52.6) 98.0 (83.5)
I/I 8.8 (2.0) 29.9 (2.7)
Refinement
Resolution range (Å) 66.6-2.40 48.1-2.40
Completeness in range (%) 94.6 (70.0) 97.7 (80.4)
Total number of reflections 68,535 72,265
Number of non-hydrogen protein atoms 6,522 6,639
Number of sulfate molecules 17 15
Number of glycerol molecules 2 2
Number of water molecules 146 86
Rfactor (%) 21.6 21.9
Rfree (%) 23.7 25.3
r.m.s.d. from ideal stereochemistry
Bond lengths (Å) 0.012 0.011
Bond angles (°) 1.45 1.39
B factors
Mean B factor (main chain) (Å3) 35.4 48.1
r.m.s.d. in main chain B factor (Å3) 0.48 0.44
Mean B factor (side chains and waters) (Å3) 38.1 49.4
r.m.s.d. in side chain B factors (Å3) 1.42 1.18
Ramachandran plot
Residues in most favored region (%) 93.0 91.7
Residues in additionally allowed regions (%) 7.0 8.3
Residues in generously allowed regions (%) 0.0 0.0
residues in disallowed regions (%) 0.0 0.0
PDB code 3EQU 3EQV
a Rmerge  Ii  Im /Ii, where Ii is the intensity of the measured reflection, and Im is the mean intensity for all observations of that reflection. Numbers within parentheses are
for the outer resolution shell of data.
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protein was defined as a separate TLS group. The stereochem-
istry of the model was monitored by PROCHECK (49). The
structure of PBP2-6140CT was refined by the same protocol.
Refinement statistics of both models are shown in Table 1.
There are twomolecules in the asymmetric unit of PBP2, and
all commonmain chain atoms can be superimposedwith a root
mean square deviation (r.m.s.d.) of 0.70 Å (the same value is
0.75 Å for PBP2-6140CT). The protein is numbered according
to the sequence of the protein in vivo. Hence, the first 44 resi-
dues, corresponding to theN-terminal tail and transmembrane
domains, are not present in the construct. Residues that were
not visible in the electron density were excluded from the
model. In bothmolecules of the asymmetric unit, 	20 residues
are absent at the N terminus, such that molecule A starts at
Asn-63 and molecule B at Ile-65. Three areas of disorder were
evident: a large area of disorder comprising residues 93–163 in
molecule A and 92–163 in molecule B, a smaller region com-
prising 502–512 inmolecule A and 504–511 inmolecule B, and
residues 213–215 that are disordered in molecule B only.
Finally, eight residues were excluded from the C terminus in
both molecules of the asymmetric unit.
The electron density shows clearly that Ser-465 of both mol-
ecules in the asymmetric is phosphorylated and, therefore, has
been modeled accordingly. This site is on the surface of the
transpeptidase domain at the N-terminal end of 10, on the
opposite side of themolecule from the active site. This apparent
modification is observed consistently in data sets collected
from different crystals of PBP2 (both wild-type and mutant)
and using proteins from different preparations. An example of
omit Fo  Fc electron density for one of these (A465) is shown
in supplemental Fig. 1. Because PBP2was expressed in the cyto-
plasm of E. coli, this phosphorylation may not be physiologi-
cally relevant.
Circular Dichroism—Each protein (PBP2, PBP2-6140, and
PBP2-6140CT)was diluted to a concentration of 0.1mg/ml in a
buffer containing 10 mM Tris, pH 8.0, 250 mM NaCl, and 10%
glycerol. The melting curves for each PBP2 construct were
measured an AVIV Biomedical Inc. Model 400 circular dichro-
ism spectrophotometer at 206 nm (corresponding to the mini-
mum in a 260-195-nm wavelength scan). Data were recorded
every degree over a temperature range of 25–75 °C. These
measurements were repeated six times (with a new sample of
protein each time) and then averaged. All spectra were cor-
rected against a control spectrum collected from buffer only,
and the mean residual ellipticity was calculated using AVIV
software. Themelting temperature (Tm) for each construct was
calculated as themidpoint of the slope between themean resid-
ual ellipticity values where the proteinwas folded and unfolded.
Mass spectrometry was used to show that the differences
observed in the melting curves were not due to different levels




The crystal structure of a soluble form of PBP2 (residues
42–581) from a penicillin-susceptible strain of N. gonorrhoeae
was solved at 2.4 Å by multiwavelength anomalous dispersion
methods using selenomethionyl-substituted protein. PBP2
contains two domains, anN-terminal domain and a C-terminal
TPase (or penicillin binding) domain that is common to all
PBPs (Fig. 1A). The N-terminal domain is an elongated domain
	45 Å in length featuring several long -strands and a subdo-
main of shorter strands and small helices. The subdomain
interacts with a protruding loop from the transpeptidase
domain in a similar way as observed in other high molecular
mass PBP structures (28, 29, 32). Within the N-terminal
domain and in bothmolecules of the crystallographic asymmet-
ric unit, residues 91–163 cannot be located in the electron den-
sity map and are presumably disordered. Mass spectrometry
confirmed this region was present in the protein construct
(data not shown).
The functional role of the N-terminal domain in PBP2 is
unknown. However, as has been suggested previously for the
C-terminal domain of PBP5 from E. coli (50), such domains
may serve to project the catalytic domain away from the cyto-
plasmic membrane toward the peptidoglycan substrate and/or
may mediate protein-protein interactions, which in this case
might target PBP2 to the septal region of the gonococcal cell.
Such interactions appear to be important for targeting E. coli
PBP3 (the homologue of PBP2) to the septum (51–54).
The TPase domain of PBP2 can be superimposed onto the
TPase domains of PBP2a from methicillin-resistant S. aureus
(28) (r.m.s.d. of 2.0 Å for 221 C atoms) and PBP2x from
S. pneumoniae (55) (r.m.s.d. of 1.6 Å for 248 C atoms) even
though it shares only 15 and 21% sequence identity with these
domains, respectively. The TPase domain can be divided into
two subdomains, an-subdomain and an/-subdomain, with
the active site lying in the groove between them. As viewed in
Fig. 1A, the-subdomain comprising helices2,4-6, and8,
lies near the top of themolecule and forms one side of the active
site groove (see Fig. 1B for secondary structure assignments).
An interesting feature of this domain is a projection of mostly
-ribbon between 2 and 4 that lies at the very top of the
molecule. In PBP2 from resistant strains ofN. gonorrhoeae, this
region contains the aspartic acid insertion found in themajority
of penA alleles (22) (see below). The /-subdomain, which
forms the lower face of the active site, contains a central core of
anti-parallel -strands (1-5) packed on both sides by several
long helices (1, 9, 10, and 11). In addition, there is an area
of apparent structural disorder between residues 502–512
(inclusive) inmolecule A (of the asymmetric unit) and 504–511
in molecule B, located in the 3-4 loop. Several of the muta-
tions observed in PBP2 variants from penicillin-resistant
strains map to this loop (see below).
Active Site
The active site of PBP2 contains three conserved sequence
motifs that are observed in nearly all penicillin-interacting
enzymes (6) (Fig. 2). The SXXKmotif is located at the N-termi-
nal end of helix 2 (shown in yellow in Fig. 2) and contains two
residues that are important for catalysis: Ser-310, the serine
nucleophile that is acylated by both peptide substrate and
-lactam antibiotics, and Lys-313. The SXNmotif, comprising
Ser-362, Ser-363,Asn-364, is present on the loop connecting4
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and 5. The KTG motif, comprising Lys-497, Thr-498, and
Gly-499, is located on strand 3. Lys-313 is a central player
in the dense network of hydrogen bonds in the active site,
where it is within hydrogen bond-
ing distance of Ser-310, Asn-364,
and the backbone carbonyl of Ser-
362. Another potential hydrogen
bond is observed between Lys-497
and Ser-362.
The overall arrangement of the
residues in the active site, including
the pattern of hydrogen bonding, is
highly similar to that seen in other
PBPs, commensurate with a com-
mon mechanism of catalysis in
PBPs. This striking overlap of active
site residues between PBPs, how-
ever, is hard to reconcile with the
vastly different second-order rates
of acylation of penicillin measured
in these PBPs (from 12 to 99,000
M1 s1) (56–58)) and suggests that
regions adjacent to the active site,
which differ markedly among PBPs,
must have a significant impact on
the penicillin acylation rate.
Modeling of a -Lactam Antibiotic
Bound in the Active Site of PBP2
Numerous attempts to produce a
complex of PBP2 with penicillin G
by crystal soaking were unsuccess-
ful; hence, penicillin G was docked
into the active site by superimpos-
ing the active site motifs of PBP2
with those of a crystal structure of
PBP5 (a D-alanine carboxypepti-
dase) from E. coli in complex with
penicillin G.4 The 10 residues corre-
sponding to the three conserved
motifs in the active sites of these
two PBPs overlapped with an
r.m.s.d. of 0.79 Å, further empha-
sizing the high degree of similarity
of the active sites within PBPs
(supplemental Fig. 2). One close
contact in the initial model, a clash
between Tyr-422 and the phenyl
ring of penicillin, was relieved by
rotation of the phenyl group of the
antibiotic. In addition, there is a
second potential clash between
the carboxylate group of penicillin
and Tyr-544, suggesting this resi-
due may hydrogen bond with the
carboxylate group in the acyl-en-
zyme complex. Interestingly,
although the orientation of the
bound antibiotic is not exactly the
4 G. Nicola, R. A. Nicholas, and C. Davies, unpublished data.
FIGURE 1. The structure of PBP2 from N. gonorrhoeae. A, a ribbon representation of the molecule in which
the structure is color-ramped blue-to-red in the N-terminal to C-terminal direction. Elements of secondary
structure are labeled according to a nomenclature scheme used previously (55). In this convention, some
elements of structure are absent in PBP2, e.g. 3 and 7. In this view, the transpeptidase domain is at the top,
and the N-terminal domain (and site of the membrane anchor) is at the bottom. B, the amino acid sequence of
wild-type PBP2 from N. gonorrhoeae (74). For the TPase domain, the standard system of nomenclature for
secondary structure is used. For the N-terminal domain, the system used for the equivalent domain in PBP2a
(28) is adopted. Regions that could not be modeled due to apparent disorder are shown as dashed lines. The
conserved motifs are highlighted by boxes. The figure was produced in part by SecSeq (D. E. Brodersen, unpub-
lished software).
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same, both of these clashes occur when cefuroxime is docked
into the active site of PBP2 in a similar way using the struc-
ture of cefuroxime-bound PBP2x (32) (not shown). In PBP2,
the clash between Tyr-544 and the penicillin carboxylate
could be relieved either by movement of the tyrosine side
chain or of the helix (11) from which it emanates. This is
important because 11 harbors mutations in PBP2 from
resistant strains that may influence the role of this helix in
antibiotic binding.
Kinetics of Interaction of PBP2 Variants with
[14C]Penicillin G
PBP2 from the penicillin-resistant chromosomally mediated
clinical isolate, FA6140 (MICpen 4g/ml) contains fivemuta-
tions compared with PBP2 from FA19: that is, an Asp-345a
insertion between positions 345 and 346 (D345a) and four
mutations clustered near the C terminus (Fig. 3). To determine
the structural effect of these mutations on the architecture of
PBP2, we attempted to crystallize PBP2 from FA6140 (termed
PBP2-6140), but the protein failed to crystallize either in the
same conditions used to produce crystals of the wild-type pro-
tein or using new screens, suggesting that one or more of the
mutations interferes with crystal packing.
For this reasonwe set out to define the distinct contributions
of the Asp-345a insertion and the C-terminal mutations to the
decrease in penicillin acylation rate in PBP2-6140. Two con-
structs were produced, one that contained only the D345a
insertion (PBP2-D345a) and one that harbored only the four
C-terminal mutations (PBP2-6140CT) (Fig. 3). These variants
were analyzed for their acylation rate constants (k2/KS) with
[14C]penicillin G as described under “Experimental Proce-
dures.” Wild-type PBP2 has a k2/KS value of 63,700 M1 s1 for
[14C]penicillin G, whereas PBP2-6140 has a k2/KS of 4,000 M1
s1, a 16-fold decrease (Table 2). The Asp-345a insertion alone
conferred an 	5-fold decrease in k2/KS (12,200 M1 s1) rela-
tive to wild-type PBP2, similar to
that previously reported (23, 59).
Surprisingly, the four C-terminal
mutations conferred an identical
5-fold decrease in k2/KS (12,400M1
s1) as the Asp-345a insertion
(Table 2).
Based on these data, we at-
tempted to crystallize both PBP2-
D345a and PBP2-6140CT. Only the
latter construct crystallized under
the same conditions as wild type,
indicating that PBP2-6140 did not
crystallize because of the presence
of the Asp-345a insertion. The
crystal structure of PBP2-6140CT
was determined to 2.4 Å resolu-
tion (see Table 1 for refinement
statistics). The overall fold of
PBP2-6140CT is essentially the
same as the wild-type enzyme (sup-
plemental Fig. 3), and all common
main atoms of bothmolecules of the
asymmetric unit superimpose with
an r.m.s.d. of 0.34 Å. The primary
change is 10 extra residues that are
visible at the N terminus in mole-
cule A of PBP2-6140CT (residues
53–62) compared with wild-type
PBP2.
FIGURE 2. Active site of PBP2 from N. gonorrhoeae. Shown are the three
conserved motifs with the SXXK motif in yellow, the SXN motif in green, and
the KTG motif in orange. Residues are shown in bond format with potential
hydrogen bonds shown as dashed lines. Distances are in Å. The fourth loop,
colored purple, is the site of the insertion of an aspartate between residues
345 and 346, which is associated with penicillin resistance.
FIGURE 3. The location of mutations within PBP2 associated with penicillin resistance. A, a diagram of the
transpeptidase domain of PBP2 showing the three active-site motifs, the site of the Asp-345a insertion, and the
four mutations near the C-terminal end of the protein that are present in PBP2-6140. WT, wild type. B, a ribbon
representation of the structure of the transpeptidase domain of PBP2 showing the location of the mutations
around the active site (containing modeled penicillin in bonds form). Each mutation is marked by a black
sphere. The orientation shown is the same as in Fig. 1A.
Crystal Structure of PBP2 from N. gonorrhoeae
JANUARY 9, 2009 • VOLUME 284 • NUMBER 2 JOURNAL OF BIOLOGICAL CHEMISTRY 1207
Effects of C-terminal Mutations on PBP2 Structure
Active Site Architecture—In structural terms, the C-terminal
mutations must alter the architecture at or around the active
site in such a way as to lower the reactivity of the enzyme for
-lactam antibiotics without significantly affecting the abil-
ity of the enzyme to catalyze transpeptidation of its natural
peptide substrate. The four mutations in PBP2-6140CT clus-
ter in two regions that are both near, but not within, the
active site. Superimposition of the active sites of wild-type
PBP2 with those of PBP2-6140CT, however, shows little or
no difference in the positions of the active site residues (Fig.
4), and any slight differences that do occur are within the
expected degree of precision in a crystal structure of this
resolution (60).
4 and 3-4 Loop—The mutations F504L, A510V, and
A516G are located on 4 or in the disordered loop that con-
nects this strand to 3 (Figs. 3B and 5A). When molecule A of
each structure is compared, there is additional density in PBP2-
6140CT, which allows the modeling of three extra residues
(Arg-502, Lys-503 and Asn-512) within the loop. In addition,
there is a very slight shift in the position of 3 such that it lies
closer to the active site in PBP2-6140CT. Two of the three
mutations in this area (F504L andA510V) remain disordered in
the 3-4 loop. The A516G mutation is located on 4 imme-
diately adjacent to the KTGmotif on3 but has very little effect
on the structure. When molecule B of each asymmetric unit is
compared, the differences are less pronounced; the length of
the disordered region is the same, and the position of 3 is
essentially unchanged.
Helix 11—The other C-terminal mutation, P551S, lies on
11, which is located toward the C terminus of the protein
(Fig. 5B). This helix is interesting because in the wild-type
enzyme it is kinked at its N-terminal end after two consecu-
tive proline residues at positions 551 and 552, and at its
C-terminal end, the side chain of Tyr-544 points directly
into the active site (where it may interact with penicillin, as
mentioned above). Surprisingly, the presence of serine at
position 551 in place of proline in PBP2-6140CT has no dis-
cernible effect on the structure of this helix, and the degree
of kinking is unchanged in the mutant enzyme. The same is
true for both molecules in the asymmetric unit. In addition,
there is no localized increase in B factors in this helix com-
pared with the surrounding structure.
One possible explanation for the lack of structural alterations
arises by examining the crystal packing interactions in this
region. In both molecules A and B of the asymmetric unit of
PBP2, the C-terminal end of11 packs against a three-stranded
 sheet of the N-terminal domain of a neighboring molecule.
Such an interaction might have reversed any alteration in the
structure of 11 present when the protein is in solution rather
than when constrained by the crystal lattice. Interestingly, the
same crystal contact appears to block the active site of PBP2
and, thus, might explain the failure to introduce -lactam com-
pounds by crystal-soaking experiments.
To define the individual contributions of the C-terminal
mutations to the decrease in penicillin acylation rate, we puri-
fied proteins containing each mutation individually and deter-
mined their effect on the k2/KS of [14C]penicillin G (Table 2).
The A510V, A516G, and F504L mutations by themselves had
minor (
2-fold) effects on k2/KS. In contrast, the P551S muta-
tion had a much larger effect on the acylation rate, with a
decrease of 3-fold relative to wild-type PBP2. Based on this
result, we examined the three other mutations in concert with
the P551S mutation. Whereas the A510V or A516G mutation
together with P551S did not appreciably change the k2/KS of
[14C]penicillin G for PBP2, the combination of P551S and
F504Lmutations decreased the acylation rate nearly to the level
of PBP2 containing all four mutations. These data indicate that
essentially all of the effects of the C-terminal mutations are due
to F504L and P551S, with the latter mutation being the most
important.
FIGURE 4. Superimposition of the active sites of wild-type PBP2 and
PBP2-6140CT. For wild type, the backbone of the protein is colored green,
and the side chain bonds are yellow, whereas for PBP2-6140CT both of these
are colored pink. Note the very close correspondence of the three active site
motifs in PBP2 derived from penicillin-susceptible and penicillin-resistant
strains of N. gonorrhoeae.
TABLE 2
k2/KS values of 
14Cpenicillin G for PBP 2 variants
PBP2 variants k2/KS Fold decrease
M1 s1
WT (n  14)a 63,700  5,500
6140 (n  10) 4,000  2,000 15.9
D345a (n  8) 12,200  2,400 5.2
6140CT (n  8) 12,400  900 5.1
F504L (n  6) 35,500  4,100 1.8
A510V (n  3) 50,200  2,700 1.3
A516G (n  5) 44,700  3,000 1.4
P551S (n  12) 21,300  800 3.0
P551S/F504L (n  7) 13,100  700 4.9
P551S/A510V (n  3) 18,800  60 3.4
P551S/A516G (n  6) 25,900  2,400 2.5
a The number of determinations of k2/KS for each construct.
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Thermal Stabilities of PBP2 Variants
To assess whether the mutations in PBP2 associated with
penicillin resistance lower the stability of protein, thermal
melting curves were determined for wild-type PBP2, PBP2-
6140, and PBP2-6140CT using circular dichroism spectros-
copy (Fig. 6). Tm values calculated from these curves were as
follows: wild-type PBP2, 54.5 °C; PBP2-6140CT, 52.0 °C;
PBP2-6140, 50.0 °C. These data show that both mutant PBPs
melt at a lower temperature than wild type, indicating that
the mutations associated with penicillin resistance impart a
destabilizing effect on the protein fold. Interestingly, the Tm
of PBP2-6140CT is intermediate between wild-type PBP2
and PBP2-6140, which correlates with the second order rate
constants of acylation.
DISCUSSION
In this study, we report the crystal structures and kinetic
analysis of PBP2 variants derived from penicillin-susceptible
and penicillin-resistant strains of N. gonorrhoeae. These
structures are the first of a PBP from N. gonorrhoeae. The
five mutations in PBP2 from the penicillin-resistant isolate
FA6140 lower the acylation rate of the enzyme for penicillin
by 16-fold, which corresponds to a 6-fold increase in MIC
(16). They are located close to but not within the active site
and can be dissected into two groups, the Asp-345a insertion
and the C-terminal mutations.
The most surprising finding from this investigation is that,
although the four C-terminalmutations together lower the rate
of acylation by 	5-fold, these amino acid changes have only
minor effects on the protein architecture. Both PBP2-6140 and
PBP-6140CT have lower thermal stabilities when compared
withwild-type PBP2, suggesting themutations are destabilizing
and that they probably increase the overall flexibility of the
protein fold. In support of this, the overall B factor of PBP-
6140CT is significantly higher than the wild-type enzyme (48
versus 35 Å2), although it should also be noted that this param-
eter is very specific for a given crystal. The lack of localized
increases in B factors around the mutation sites also supports
the idea of a global increase in flexibility.
These observations can be explained in two ways; 1) The
mutations lead to a slight disordering of the structure that is too
small in displacement to observe by x-ray crystallography but
which nevertheless has a significant effect on the kinetics, or 2)
there is a dynamic equilibrium between conformational states
of the enzyme,where one state exhibits higher acylation activity
than the other, and that increased flexibility caused by the
mutations in PBP2-6140 shifts this equilibrium toward the less
active state. The inability to observe these two states by x-ray
crystallography is because, in the crystal, both wild-type and
mutant PBP2 have been “frozen” in the same conformational
state.
The distribution of the mutations associated with penicil-
lin resistance around (but not within) the active site is also
consistent with a mechanism of generalized disordering that
FIGURE 5. The effect of mutations associated with penicillin resistance on the structure of PBP2 from N. gonorrhoeae. In this picture, the crystal
structures of wild-type PBP2 (green) and PBP2-6140CT (pink) are superimposed. The location of the active site is indicated by the modeled penicillin molecule
(gray bonds), and sites of mutations are labeled in red. Elements of secondary structure and selected amino acids are labeled, including those at the active site.
A, 3 region, including the 3-4 disordered loop. B, 11 region.
FIGURE 6. Thermal stabilities of wild-type and mutant PBP2s. Melting
curves were determined using circular dichroism by measuring the mean
ellipticity at 206 nm in 1 °C intervals. f, wild-type PBP2; Œ, PBP2-6140CT; F,
PBP2-6140.
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lowers reactivity with penicillin. A similar pattern of muta-
tions has been observed in several other unrelated systems,
suggesting this may be a general phenomenon of resistance.
For example, mutations in Drosophila acetylcholinesterase
associated with resistance to inhibitors are located in the
second shell of residues around the active site (61), and a
study of a drug-resistant HIV-1 protease showed that resi-
dues that lie outside the active site can be the primary source
of resistance (62). In cytochrome P450 14-sterol demethy-
lases (CYP51) from azole-resistant Candida albicans, muta-
tions appear to prevent key conformational changes but do
not contact the inhibitor directly (63).
The increased flexibility in PBP2 could affect binding affinity
or acylation. The non-covalent binding affinity of penicillin
(KS) could be lowered by hindering the conformational changes
required for binding, i.e. it would increase the energetic cost
associated with induced fit. Many PBPs undergo conforma-
tional changes upon binding -lactams, including E. coli PBP4
(64), S. pneumoniae PBP1b (65), S. pneumoniae PBP2x (66),
and E. coli PBP5.4 The apparent clashes with penicillin in the
model of the acylated enzyme suggest that conformational
changes are also required in PBP2. Moreover, the P551S muta-
tion,which has the greatest effect on k2/KS, is located at the kink
in 11 and might prevent or alter the movement of Tyr-544 (at
the N-terminal end of 11) during acylation. The other impor-
tant mutation, F504L, is on the disordered 3-4 loop and
could influence the position of 3, which does shift slightly in
PBP2-6140CT (see Fig. 5A).
Increased flexibility of PBP2 could also lower the rate of
acylation by increasing the energetic cost required to form
the tetrahedral intermediate for catalysis. Such a state
requires very precise geometry to permit catalysis, and
increased flexibility in the active site region would make it
less likely that such a state is attained. In both mechanisms
(reduced binding affinity or acylation), the reactivity of pep-
tide would be less affected than penicillin because both
effects can be overcome by a proportionally larger number of
interactions between the protein and its substrate. In addi-
tion, the impact of lowered affinity for peptide would be
lessened by the proximity of PBP2 to peptidoglycan, which
increases the effective concentration of its substrate.
The apparent mechanism of penicillin resistance in N. gon-
orrhoeae, which involves very subtle alterations in PBP2 due to
destabilizing mutations, contrasts with investigations in other
PBPs. In the case of PBP2a derived from methicillin-resistant
S. aureus, it was proposed that the low rate of acylation by
-lactams resulted from a remodeling of the active site involv-
ing a twisting of 3 and a shift in 2. These changes, which
presumably occurred during the evolution of PBP2a from pen-
icillin-sensitive progenitor, increased the energetic penalty for
transitioning from the initialMichaelis-Menten complex to the
acyl-enzyme intermediate (28). In support of this hypothesis,
mutations in PBP2x from the penicillin-resistant strain of
S. pneumoniae sp5259 cause a small shift in the position of 3
(34), and we also observe a slight shift in the same strand in
PBP2. In the case of PBP2a, though, the argumentwas premised
upon the observation (at that time) that PBPs do not undergo
significant conformational changes upon reacting with -lac-
tams and that in PBP2a the remodeling meant that conforma-
tional changes were now required to form the acyl-enzyme
complex. However, several structures of PBPs solved since then
show that conformational changes do indeed occurwhen form-
ing the acyl-enzyme intermediate (see above). Nevertheless, it
is interesting to note that two of the fourmutations in PBP2 are
located in the 3-4 loop, thus implicating this region as being
important for penicillin resistance in more than one PBP.
Many studies have linked penicillin resistance mediated by
mutations in PBP2x from S. pneumoniae with significant
changes in crystal structures, including disordering of a loop
that precedes the SXNmotif (27, 33, 34). The contrast between
such large alterations in PBP2x and the lack of significant struc-
tural differences in PBP2-6140CT is very striking and points to
differentmechanisms of resistance operating in each organism.
One reason for this might be the lack of an outer membrane in
Gram-positive bacteria. Thus, alterations in PBPs in S. pneu-
moniae contribute proportionally more to resistance than in
N. gonorrhoeaewhere other mechanisms, such as alterations in
porins and efflux pumps, are also involved. In addition, the sub-
tle changes in PBP2 from N. gonorrhoeae probably have little
impact on the reactivity of the enzyme with its peptide sub-
strates, whereas the changes in PBP2x would be expected to
alter the reactivity of the enzyme for both peptide substrates
and -lactams. In keeping with this hypothesis, peptidoglycan
isolated from penicillin-resistant strains of S. pneumoniae
shows a higher degree of peptide branching than that isolated
from susceptible strains (67, 68). Although the structure of pep-
tidoglycan from penicillin-resistant strains of N. gonorrhoeae
has not been analyzed, only minor differences have been
observed in strains ofN.meningitidis that have reduced suscep-
tibility to penicillin (69).
Absent from the discussion thus far is the effect on penicillin
resistance contributed by the insertion of Asp-345a. Because
the aspartate insertion is the onemutation observedmost often
in penicillin-resistant strains (22), it was considered the most
important for lowering reactivity with penicillin, with the other
mutations having only a slight (	2-fold) effect on the protein
(23). However, as shown here, the four C-terminalmutations in
PBP2 from FA6140 have an identical effect on the second order
rate of acylation as the Asp-345a insertion by itself (Table 2).
These data suggest that the two types of alterations are mildly
antagonistic to one another, as one would expect a nearly
25-fold decrease (the product of the two) if the mutations were
independent.
The site of mutation is on a hairpin loop that lies near the
SXNmotif of the active site (Fig. 7). Interestingly, the equivalent
loop in PBP5fm from Enterococcus faecium also contains an
insertion mutation (of a serine) that is present in the most pen-
icillin-resistant strains (70, 71). Unfortunately, none of the con-
structs of PBP2 containing Asp-345a crystallized, leaving the
exact structural consequences of this mutation unclear. Exam-
ination of this region in the wild-type structure of PBP2,
though, shows that the side chain of Asp-346, which is imme-
diately adjacent to the insertion site, forms hydrogen bonds
with the side chain hydroxyl of Ser-363 (theX of the SXNmotif)
and the amide nitrogens of Asn-364 and Val-365. Insertion of
an aspartate before Asp-346may disrupt these interactions and
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affect enzyme activity by altering the conformation of the SXN
motif. Although it might be expected that such an insertion
would cause disordering of the hairpin loop, it should be noted
that the insertion of an aspartate is the only amino acid that
confers penicillin resistance to N. gonorrhoeae (23), arguing in
favor of a more specific mechanism to lower acylation by pen-
icillin. One intriguing possibility is that the inserted aspartate
replaces the existing aspartate at position 346 and assumes
some or all of the hydrogen bonds mediated by that residue.
This may explain why only an aspartate can be inserted and not
a glutamate, for instance, because the same arrangement may
not be possible with the longer side chain. Clearly, the balance
between developing penicillin resistance and maintaining
transpeptidase activity is very delicate.
In conclusion, the molecular mechanism of penicillin
resistance in PBP2 contributed by the four mutations toward
the C-terminal end of the protein, and in particular P551S
and F504L, appears to be very subtle in nature and very dif-
ferent from the large structural changes observed in PBP2x
from S. pneumoniae. Although this result might seem unex-
pected, in hindsight a microscopic rather than macroscopic
mechanism of resistance is logical given the strict con-
straints placed on the evolution of resistance by the necessity
to retain activity with peptides while lowering that for -lac-
tams. By contrast, the effect of Asp-345a is expected to be
more significant both in terms of its potential to alter struc-
ture and its proximity to an active site motif. Clearly, there
remains much to understand, and a key goal now is to view
both wild-type and mutant PBP2 in complexes with -lac-
tam antibiotics. With the recent emergence of gonococcal
strains showing intermediate resistance to third-generation
cephalosporins caused in part by mutations in PBP2 (2, 5, 72,
73), such investigation is of high priority.
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